Study Summary
This is a single-center, prospective clinical study evaluating safety and efficacy of C-CAR011 treatment in subjects with ALL after HSCT
Interested in this trial?
Submit an InquiryInterventions
C-CAR011BIOLOGICAL
CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Peking University Institute of Hematology | Beijing | Beijing Municipality | China |